Afm13 News Today

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.

The FDA has granted fast track designation to the first-in-class innate cell engager AFM13 plus AlloNK for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic activity of AB-101 against tumor cells and... | June 9, 2023

A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory peripheral T cell lymphoma is accepted as a poster presentationA trial in progress abstract of the... | May 11, 2023

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

Message : Required fields -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM...